Hou et al., in their observational cohort study, showed that women with adenomyosis had better clinical pregnancy rates ((OR 1.925, 95% CI 1.137-3.250, p=0.015), implantation rates (OR 1.694, 95% CI 1.006-2.854, p=0.047), and live birth rates (OR 1.704, 95% CI 1.012-2.859, p=0.044) when they receive ultralong GnRH agonist protocol when compared to the luteal GnRH agonist protocol [21]. Here, GNRH1 is linked to adenomyosis.